Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BHVNBearishAnalyst Ratingnews

High materiality7/10

BofA Downgrade to Underperform Pressures Biohaven, Target Reduced to $11

Jun 29, 2026, 8:41 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Downgrade to Underperform with a $11 PT and immediate 5.2% pre-market decline indicate near-term downside risk; biotech names are sensitive to analyst shifts, often causing multi-day to weeks of volatility.

AI summary

What happened, with direct paths to the underlying reporting

Bank of America Securities downgraded Biohaven (BHVN) to Underperform and cut the target from $12 to $11. The stock dropped 5.2% to about $15 in pre-market trading, signaling near-term downside risk. If sentiment remains negative or catalysts disappoint, BHVN could test the low-teens in the coming sessions.

BofA Securities downgrades Biohaven to Underperform; price target trimmed to $11.
Biohaven shares fall 5.2% pre-market to $15 on the downgrade.
Nasdaq 100 futures rise >1%, setting a mixed market backdrop.
Near-term BHVN downside risk increases if the rating sticks or sentiment worsens.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

BofA Downgrade to Underperform Pressures Biohaven, Target Reduced to $11

Biohaven advances Vyglxia SCA filing; advisory input likely in 2027

Biohaven-Ono Asia license: $80M upfront, 20% royalties, non-dilutive cash

Biohaven Faces FDA Partial Clinical Hold on Epilepsy Program; Shares Fall

Biohaven secures SK licensing deal and Yale IP victory, boosting upside